Immunologic endocrine disorders

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 2 SUPPL. 2, 2010, Pages

  Michels, Aaron W ^a   Eisenbarth, George S ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

Addison disease; autoantibodies; autoimmune polyendocrine syndrome type 1; autoimmune polyendocrine syndrome type 2; Graves disease; HLA; iatrogenic autoimmunity; immunotherapy; polyendocrine autoimmunity; Type 1 diabetes

Indexed keywords

ABATACEPT; ALEMTUZUMAB; ALPHA INTERFERON; BHT 3021; CALCITRIOL; CALCIUM; CD20 ANTIBODY; CYCLOSPORIN; DACLIZUMAB; GLUCOCORTICOID; GLUTAMATE DECARBOXYLASE 65; INFLIXIMAB; INSULIN; INTERLEUKIN 2; IPILIMUMAB; MAGNESIUM; METHOTREXATE; METHYLPREDNISOLONE; MINERALOCORTICOID; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID; NICOTINAMIDE; PROINSULIN; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THIAMAZOLE; THYMOCYTE ANTIBODY; THYROXINE; UNCLASSIFIED DRUG;

ADDISON DISEASE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; AUTOIMMUNE THYROIDITIS; CELIAC DISEASE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; ENDOCRINE DISEASE; ENDOCRINE OPHTHALMOPATHY; GENETIC SUSCEPTIBILITY; GRAVES DISEASE; HASHIMOTO DISEASE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPOPHYSITIS; HYPOTHYROIDISM; IDIOPATHIC HYPOPARATHYROIDISM; IMMUNOGENETICS; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; IPEX SYNDROME; KIDNEY CARCINOMA; KIDNEY METASTASIS; MELANOMA; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; POEMS SYNDROME; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; THYROIDITIS; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; ENDOCRINE SYSTEM DISEASES; HUMANS; IATROGENIC DISEASE; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; NEOPLASMS; ORGAN SPECIFICITY; VIRUS DISEASES;

EID: 76749144995     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.09.053     Document Type: Article

References (90)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 31 suppl 1 (2008) S55-S60
2. Harjutsalo V., Sjoberg L., and Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 371 (2008) 1777-1782
3. Erlich H., Valdes A.M., Noble J., Carlson J.A., Varney M., Concannon P., et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 57 (2008) 1084-1092
4. Murphy R., Ellard S., and Hattersley A.T. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 4 (2008) 200-213
5. Redondo M.J., Jeffrey J., Fain P.R., Eisenbarth G.S., and Orban T. Concordance for islet autoimmunity among monozygotic twins. N Engl J Med 359 (2008) 2849-2850
6. Redondo M.J., Fain P.R., Krischer J.P., Yu L., Cuthbertson D., Winter W.E., et al. Expression of beta-cell autoimmunity does not differ between potential dizygotic twins and siblings of patients with type 1 diabetes. J Autoimmun 23 (2004) 275-279
7. Bonifacio E., Pfluger M., Marienfeld S., Winkler C., Hummel M., and Ziegler A.G. Maternal type 1 diabetes reduces the risk of islet autoantibodies: relationships with birthweight and maternal HbA(1c). Diabetologia 51 (2008) 1245-1252
8. Lie B.A., Ronningen K.S., Akselsen H.E., Thorsby E., and Undlien D.E. Application and interpretation of transmission/disequilibrium tests: transmission of HLA-DQ haplotypes to unaffected siblings in 526 families with type 1 diabetes. Am J Hum Genet 66 (2000) 740-743
9. Todd J.A., Walker N.M., Cooper J.D., Smyth D.J., Downes K., Plagnol V., et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39 (2007) 857-864
10. Pugliese A., Zeller M., Fernandez Jr. A., Zalcberg L.J., Bartlett R.J., Ricordi C., et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 15 (1997) 293-297
11. Vang T., Congia M., Macis M.D., Musumeci L., Orru V., Zavattari P., et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 37 (2005) 1317-1319
12. Grant S.F., Qu H.Q., Bradfield J.P., Marchand L., Kim C.E., Glessner J.T., et al. Follow-up analysis of genome-wide association data identifies novel loci for type 1 diabetes. Diabetes 58 (2009) 290-295
13. Harjutsalo V., Sjoberg L., and Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 371 (2008) 1777-1782
14. Norris J.M., Yin X., Lamb M.M., Barriga K., Seifert J., Hoffman M., et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA 298 (2007) 1420-1428
15. Norris J.M., Barriga K., Klingensmith G., Hoffman M., Eisenbarth G.S., Erlich H., et al. Timing of cereal exposure in infancy and risk of islet autoimmunity. The Diabetes Autoimmunity Study in the Young (DAISY). JAMA 290 (2003) 1713-1720
16. Norris J.M., Yin X., Lamb M.M., Barriga K., Seifert J., Hoffman M., et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA 298 (2007) 1420-1428
17. Uusitalo L., Nevalainen J., Niinisto S., Alfthan G., Sundvall J., Korhonen T., et al. Serum alpha- and gamma-tocopherol concentrations and risk of advanced beta cell autoimmunity in children with HLA-conferred susceptibility to type 1 diabetes mellitus. Diabetologia 51 (2008) 773-780
18. Waterland R.A., and Jirtle R.L. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 23 (2003) 5293-5300
19. Fraga M.F., Ballestar E., Paz M.F., Ropero S., Setien F., Ballestar M.L., et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 102 (2005) 10604-10609
20. Wenzlau J.M., Juhl K., Yu L., Moua O., Sarkar S.A., Gottlieb P., et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 104 (2007) 17040-17045
21. Moriyama H., Wen L., Abiru N., Liu E., Yu L., Miao D., et al. Induction and acceleration of insulitis/diabetes in mice with a viral mimic (polyinosinic-polycytidylic acid) and an insulin self-peptide. Proc Natl Acad Sci U S A 99 (2002) 5539-5544
22. Hutton J.C., and Eisenbarth G.S. A pancreatic β-cell-specific homolog of glucose-6-phosphatase emerges as a major target of cell-mediated autoimmunity in diabetes. Proc Natl Acad Sci U S A 100 (2003) 8626-8628
23. Willcox A., Richardson S.J., Bone A.J., Foulis A.K., and Morgan N.G. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 155 (2009) 173-181
24. Achenbach P., Bonifacio E., and Ziegler A.G. Predicting type 1 diabetes. Curr Diab Rep 5 (2005) 98-103
25. Verge C.F., Gianani R., Kawasaki E., Yu L., Pietropaolo M., Jackson R.A., et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45 (1996) 926-933
26. Achenbach P., Warncke K., Reiter J., Williams A.J., Ziegler A.G., Bingley P.J., et al. Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody-positive relatives. Diabetologia 49 (2006) 2969-2976
27. Wenzlau J.M., Moua O., Sarkar S.A., Yu L., Rewers M., Eisenbarth G.S., et al. SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann N Y Acad Sci 1150 (2008) 256-259
28. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
29. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., et al. A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in c-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54 (2005) 1763-1769
30. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352 (2005) 2598-2608
31. Jenner M., Bradish G., Stiller C., and Atkison P. Cyclosporin A treatment of young children with newly-diagnosed type 1 (insulin-dependent) diabetes mellitus. London Diabetes Study Group. Diabetologia 35 (1992) 884-888
32. Elliott R.B., and Chase H.P. Prevention or delay of type I (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 34 (1991) 362-365
33. Allen H.F., Klingensmith G.J., Jensen P., Simoes E., Hayward A., and Chase H.P. Effect of BCG vaccination on new-onset insulin-dependent diabetes mellitus: a randomized clinical study. Diabetes Care 22 (1998) 1703-1707
34. Ludvigsson J., Faresjo M., Hjorth M., Axelsson S., Cheramy M., Pihl M., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359 (2008) 1909-1920
35. Staeva-Vieira T., Peakman M., and von Herrath M. Translational mini-review series on type 1 diabetes: immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 148 (2007) 17-31
36. *0406. J Clin Endocrinol Metab 77 (1993) 249-254
37. Marga M., Denisova A., Sochnev A., Pirags V., and Farid N.R. Two HLA DRB 1 alleles confer independent genetic susceptibility to Graves disease: relevance of cross-population studies. Am J Med Genet 102 (2001) 188-191
38. *07 is protective. J Clin Endocrinol Metab 84 (1999) 3182-3186
39. Martin A., Nakashima M., Zhou A., Aronson D., Werner A.J., and Davies T.F. Detection of major T cell epitopes on human thyroid stimulating hormone receptor by overriding immune heterogeneity in patients with Graves' disease. J Clin Endocrinol Metab 82 (1997) 3361-3366
40. Gillis D., Volpe R., and Daneman D. A young boy with a thyroid yo-yo. J Pediatr Endocrinol Metab 11 (1998) 467-470
41. Weetman A.P. Graves' disease. N Engl J Med 343 (2000) 1236-1248
42. Starkey K.J., Janezic A., Jones G., Jordan N., Baker G., and Ludgate M. Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J Mol Endocrinol 30 (2003) 369-380
43. El Fassi D., Nielsen C.H., Bonnema S.J., Hasselbalch H.C., and Hegedus L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab 92 (2007) 1769-1772
44. Salvi M., Vannucchi G., Campi I., Curro N., Dazzi D., Simonetta S., et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156 (2007) 33-40
45. Ban Y., Greenberg D.A., Concepcion E., Skrabanek L., Villanueva R., and Tomer Y. Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease. Proc Natl Acad Sci U S A 100 (2003) 15119-15124
46. Ban Y., Davies T.F., Greenberg D.A., Kissin A., Marder B., Murphy B., et al. Analysis of the CTLA-4, CD28, and inducible costimulator (ICOS) genes in autoimmune thyroid disease. Genes Immun 4 (2003) 586-593
47. Sommers S.C. Adrenal glands. In: Kissane J.M. (Ed). Anderson's pathology (2002), CV Mosby, St Louis 1429-1450
48. Eisenbarth G.S., and Gottlieb P.A. Autoimmune polyendocrine syndromes. N Engl J Med 350 (2004) 2068-2079
49. Betterle C., Volpato M., Rees Smith B., Furmaniak J., Chen S., Zanchetta R., et al. II. Adrenal cortex and steroid 21-hydroxylase autoantibodies in children with organ-specific autoimmune diseases: markers of high progression to clinical Addison's disease. J Clin Endocrinol Metab 82 (1997) 939-942
50. Gambelunghe G., Falorni A., Ghaderi M., Laureti S., Tortoioli C., Santeusanio F., et al. Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison' disease. J Clin Endocrinol Metab 84 (1999) 3701-3707
51. Hue S., Monteiro R.C., Berrih-Aknin S., and Caillat-Zucman S. Potential role of NKG2D/MHC class I-related chain A interaction in intrathymic maturation of single-positive CD8 T cells. J Immunol 171 (2003) 1909-1917
52. Maasho K., Opoku-Anane J., Marusina A.I., Coligan J.E., and Borrego F. NKG2D is a costimulatory receptor for human naive CD8+ T cells. J Immunol 174 (2005) 4480-4484
53. Alimohammadi M., Bjorklund P., Hallgren A., Pontynen N., Szinnai G., Shikama N., et al. Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N Engl J Med 358 (2008) 1018-1028
54. Kifor O., Moore Jr. F.D., Delaney M., Garber J., Hendy G.N., Butters R., et al. A syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor. J Clin Endocrinol Metab 88 (2003) 60-72
55. Bakalov V.K., Anasti J.N., Calis K.A., Vanderhoof V.H., Premkumar A., Chen S., et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46, XX spontaneous premature ovarian failure. Fertil Steril 84 (2005) 958-965
56. Hill J.A., Welch W.R., Faris H.M., and Anderson D.J. Induction of class II major histocompatibility complex antigen expression in human granulosa cells by interferon gamma: a potential mechanism contributing to autoimmune ovarian failure. Am J Obstet Gynecol 162 (1990) 534-540
57. Caturegli P., Lupi I., Landek-Salgado M., Kimura H., and Rose N.R. Pituitary autoimmunity: 30 years later. Autoimmun Rev 7 (2008) 631-637
58. Blansfield J.A., Beck K.E., Tran K., Yang J.C., Hughes M.S., Kammula U.S., et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28 (2005) 593-598
59. Kristof R.A., Van R.D., Klingmuller D., Springer W., and Schramm J. Lymphocytic hypophysitis: non-invasive diagnosis and treatment by high dose methylprednisolone pulse therapy?. J Neurol Neurosurg Psychiatry 67 (1999) 398-402
60. Anderson M.S., Venanzi E.S., Klein L., Chen Z., Berzins S.P., Turley S.J., et al. Projection of an immunological self shadow within the thymus by the AIRE protein. Science 298 (2002) 1395-1401
61. Kumar P.G., Laloraya M., and She J.X. Population genetics and functions of the autoimmune regulator (AIRE). Endocrinol Metab Clin North Am 31 (2002) 321-338 vi
62. Ramsey C., Winqvist O., Puhakka L., Halonen M., Moro A., Kampe O., et al. Aire deficient mice develop multiple features of APECED phenotype and show altered immune response. Hum Mol Genet 11 (2002) 397-409
63. Meyer G., Donner H., Herwig J., Bohles H., Usadel K.H., and Badenhoop K. Screening for an AIRE-1 mutation in patients with Addison's disease, type 1 diabetes, Graves' disease and Hashimoto's thyroiditis as well as in APECED syndrome. Clin Endocrinol (Oxf) 54 (2001) 335-338
64. Meager A., Visvalingam K., Peterson P., Moll K., Murumagi A., Krohn K., et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 3 (2006) e289
65. Perheentupa J. APS-I/APECED: The clinical disease and therapy. In: Eisenbarth G.S. (Ed). Autoimmune polyendocrine syndromes (2002), W.B. Saunders Company, Philadelphia 295-320
66. Eisenbarth G.S., Wilson P.W., Ward F., Buckley C., and Lebovitz H.E. The polyglandular failure syndrome: disease inheritance, HLA- type and immune function. Ann Intern Med 91 (1979) 528-533
67. Michels A.W., and Eisenbarth G.S. Autoimmune polyendocrine syndrome type 1 (APS-1) as a model for understanding autoimmune polyendocrine syndrome type 2 (APS-2). J Intern Med 265 (2009) 530-540
68. *04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. J Clin Endocrinol Metab 84 (1999) 328-335
69. Bacchetta R., Passerini L., Gambineri E., Dai M., Allan S.E., Perroni L., et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 116 (2006) 1713-1722
70. Ziegler S.F. FOXP3: of mice and men. Annu Rev Immunol 24 (2006) 209-226
71. Le B.S., and Geha R.S. IPEX and the role of Foxp3 in the development and function of human Tregs. J Clin Invest 116 (2006) 1473-1475
72. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27 (2001) 68-73
73. Khattri R., Cox T., Yasayko S.A., and Ramsdell F. An essential role for Scurfin in CD4+ CD25+ T regulatory cells. Nat Immunol 4 (2003) 337-342
74. Singh N., Chandler P.R., Seki Y., Baban B., Takezaki M., Kahler D.J., et al. Role of CD28 in fatal autoimmune disorder in scurfy mice. Blood 110 (2007) 1199-1206
75. Patel D.D. Escape from tolerance in the human X-linked autoimmunity-allergic disregulation syndrome and the scurfy mouse. J Clin Invest 107 (2001) 155-157
76. Mazzolari E., Forino C., Fontana M., D'Ippolito C., Lanfranchi A., Gambineri E., et al. A new case of IPEX receiving bone marrow transplantation. Bone Marrow Transplant 35 (2005) 1033-1034
77. Creange A., Chater A., Brouet J.C., Jaccard A., Rahmouni A., Lefaucheur J.P., et al. A case of POEMS syndrome treated by autologous hematopoietic stem-cell transplantation. Nat Clin Pract Neurol 4 (2008) 686-691
78. Rewers M., Liu E., Simmons J., Redondo M.J., and Hoffenberg E.J. Celiac disease associated with type 1 diabetes mellitus. Endocrinol Metab Clin North Am 33 (2004) 197-214 xi
79. Farrell R.J., and Kelly C.P. Celiac sprue. N Engl J Med 346 (2002) 180-188
80. Barker J.M., Yu J., Yu L., Wang J., Miao D., Bao F., et al. Autoantibody "sub-specificity" in type 1 diabetes: risk for organ specific autoimmunity clusters in distinct groups. Diabetes Care 28 (2005) 850-855
81. Umpierrez G.E., Latif K.A., Murphy M.B., Lambeth H.C., Stentz F., Bush A., et al. Thyroid dysfunction in patients with type 1 diabetes: a longitudinal study. Diabetes Care 26 (2003) 1181-1185
82. Silverstein J., Klingensmith G., Copeland K., Plotnick L., Kaufman F., Laffel L., et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 28 (2005) 186-212
83. Perros P., Singh R.K., Ludlam C.A., and Frier B.M. Prevalence of pernicious anaemia in patients with type 1 diabetes mellitus and autoimmune thyroid disease. Diabetes Med 17 (2000) 749-751
84. Russo M.W., and Fried M.W. Side effects of therapy for chronic hepatitis C. Gastroenterology 124 (2003) 1711-1719
85. Schreuder T.C., Gelderblom H.C., Weegink C.J., Hamann D., Reesink H.W., Devries J.H., et al. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int 28 (2007) 39-46
86. Weijl N.I., Van der Harst D., Brand A., Kooy Y., Van L.S., Schroder J., et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 11 (1993) 1376-1383
87. Maker A.V., Yang J.C., Sherry R.M., Topalian S.L., Kammula U.S., Royal R.E., et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 29 (2006) 455-463
88. Blansfield J.A., Beck K.E., Tran K., Yang J.C., Hughes M.S., Kammula U.S., et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28 (2005) 593-598
89. Jones J.L., and Coles A.J. Campath-1H treatment of multiple sclerosis. Neurodegener Dis 5 (2008) 27-31
90. Chen F., Day S.L., Metcalfe R.A., Sethi G., Kapembwa M.S., Brook M.G., et al. Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine (Baltimore) 84 (2005) 98-106